AI464131 Inhibitors
AI464131 inhibitors represent a novel class of compounds specifically designed to target and modulate the activity of the AI464131 protein. This protein is believed to play a critical role in a variety of biochemical pathways, particularly those related to cellular signaling and regulatory mechanisms. AI464131 inhibitors function by binding to key active sites on the protein, thus obstructing its ability to participate in normal enzymatic functions. These interactions are highly specific, relying on the structural conformation of the inhibitor molecule and the active site of the AI464131 protein. The inhibitors can be either reversible or irreversible, depending on the nature of their binding to the target site. Reversible inhibitors typically form non-covalent bonds, such as hydrogen bonds, van der Waals forces, or ionic interactions, while irreversible inhibitors form covalent bonds that permanently block the active site. This specificity makes AI464131 inhibitors valuable tools in the investigation of AI464131-mediated pathways, allowing researchers to selectively disrupt certain biological processes to study their underlying mechanisms.
The structural design of AI464131 inhibitors generally includes functional groups that enhance their affinity and selectivity toward the target protein. For instance, molecular scaffolds incorporating heteroatoms such as nitrogen or oxygen may improve binding specificity by forming key interactions with the AI464131 protein's amino acid residues. Additionally, modifications such as halogenation or methylation can further optimize the inhibitor's physicochemical properties, such as solubility, stability, and permeability. Some AI464131 inhibitors may also exhibit allosteric effects, whereby the inhibitor binds to a region of the protein distinct from the active site, inducing conformational changes that reduce the protein's activity. These inhibitors serve as invaluable chemical tools in understanding the structural biology of AI464131 and in elucidating its role in complex cellular processes. By leveraging the structural and functional properties of AI464131 inhibitors, researchers can gain deeper insights into protein-protein interactions, signal transduction, and other critical cellular events.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Acarbose | 56180-94-0 | sc-203492 sc-203492A | 1 g 5 g | $226.00 $605.00 | 1 | |
Acarbose inhibits alpha-glucosidases, enzymes that break down carbohydrates into glucose. Inhibition of these enzymes can reduce the availability of simple sugars necessary for glycosylation processes, potentially disrupting the glycosylation of the myogenesis regulating glycosidase (putative) and inhibiting its function. | ||||||
Miglitol | 72432-03-2 | sc-221943 | 10 mg | $161.00 | 1 | |
Miglitol functions similarly to Acarbose by inhibiting alpha-glucosidases. The inhibition of carbohydrate breakdown could interfere with the glycosylation state of the myogenesis regulating glycosidase (putative), thus impairing its biological activity. | ||||||
Voglibose | 83480-29-9 | sc-204384 sc-204384A | 10 mg 50 mg | $198.00 $681.00 | ||
Voglibose is another alpha-glucosidase inhibitor, which could limit the supply of glucose for glycosylation reactions within the cell. Consequently, this may result in inadequate glycosylation of the myogenesis regulating glycosidase (putative), thereby inhibiting its activity. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
Castanospermine inhibits glucosidase I and II, key enzymes in the N-linked glycosylation pathway. By inhibiting these enzymes, castanospermine could prevent proper folding and function of the myogenesis regulating glycosidase (putative) due to insufficient glycosylation. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $73.00 $145.00 | ||
Deoxynojirimycin inhibits several glucosidases and could thereby impair the post-translational modification of the myogenesis regulating glycosidase (putative). This inhibition may lead to misfolded glycoproteins and potentially decrease the functional capacity of the glycosidase. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Swainsonine inhibits mannosidase II, an enzyme involved in glycoprotein processing. This inhibition can disrupt the normal processing and maturation of glycoproteins, potentially leading to an inactive form of the myogenesis regulating glycosidase (putative). | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $135.00 $540.00 $1025.00 $6248.00 | 25 | |
Kifunensine inhibits mannosidase I, an enzyme involved in the modification of N-linked glycosylation. Inhibition of mannosidase I could result in incorrect processing of glycoproteins, potentially inhibiting the function of the myogenesis regulating glycosidase (putative). | ||||||
Celgosivir | 121104-96-9 | sc-488385 sc-488385A sc-488385B | 5 mg 25 mg 100 mg | $525.00 $902.00 $2700.00 | ||
Celgosivir is a prodrug of castanospermine and functions as a glucosidase I inhibitor. By inhibiting this enzyme, celgosivir might impair the folding and maturation of the myogenesis regulating glycosidase (putative), leading to its functional inhibition. | ||||||
(Z)-Pugnac | 132489-69-1 | sc-204415A sc-204415 | 5 mg 10 mg | $224.00 $380.00 | 3 | |
PUGNAc is an inhibitor of O-GlcNAcase, which is involved in the removal of O-GlcNAc from proteins. By inhibiting this enzyme, PUGNAc could alter protein glycosylation, potentially affecting the function and stability of the myogenesis regulating glycosidase (putative). | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin blocks N-linked glycosylation by inhibiting the first step in the dolichol-linked oligosaccharide pathway. This inhibition can prevent the addition of oligosaccharides to the myogenesis regulating glycosidase (putative), leading to its functional inhibition due to incorrect glycosylation. | ||||||